Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/00b08d82-ecba-4c02-9a50-0ba31b6f972c/

AKUMS

AKUMS DRUGS AND PHARMA L
Chart
701.95 INR
Latest Week 2026-07-10
HealthcareDrug Manufacturers - Specialty & GenericLARGE
Snapshot 2026-07-12 · 0.6w · Fresh
0.88
OS Score
62.0%
Value
79.0%
Quality
83.0%
Momentum
6/9
F-Score
0.700
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
2 of 23 passing
★
OS Composite
OS 0.880
↗
Trending Value
✗
◆
Quality × Value
QV 0.700
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
62.0%ile
P/E
42.1×
P/S
2.5×
P/B
3.2×
E/P
0.0348
FCF Yield
0.090
EBITDA/EV
0.059
SH Yield
0.004
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
41.00000000
/100 — 1=cheapest
VC2 (Trending Value)
37.00000000
/100
VC3 (Buyback)
59.00000000
/100
P/E of 42.1x is premium-priced — the market is paying up for expected growth. FCF yield of 9.0% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
79.0%ile
ROE
0.077
ROA
0.047
Net Margin
0.059
Op Margin
0.084
GPA
0.339
Current
3.25
F-Score
6/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.044
Earn Growth
-0.245
Stability
0.504
lower=better
Accruals
-0.170
lower=better
5yr Consist
No
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
83.0%ile
6M Return
57.8%
12M Return
25.8%
12-1 Mom
11.1%
Risk-Adj
0.37
Vol 252d
30.0%
Vol 60d
67.1%
↑ Expanding
Max DD 12M
-24.0%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (67%) is expanding vs long-term (30%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.88
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 160 peers
Sector Value %ile
86.3%
Sector Quality %ile
62.7%
P/E z-score
-0.18
P/B z-score
-0.54
Sector Avg OS
41.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
LINCOLN Lincoln Pharmaceuticals Limited 97.0% 89.0% 80.0% 79.0%
NATCOPHARM NATCO Pharma Limited 96.0% 86.0% 88.0% 68.0%
SPARC Sun Pharma Advanced Research Company Limited 96.0% 71.0% 91.0% 94.0%
VENUSREM Venus Remedies Limited 96.0% 68.0% 95.0% 99.0%
STAR Strides Pharma Science Limited 95.0% 75.0% 91.0% 84.0%
AUROPHARMA Aurobindo Pharma Limited 95.0% 73.0% 83.0% 90.0%
LUPIN Lupin Limited 94.0% 64.0% 98.0% 86.0%
SAGILITY Sagility Limited 93.0% 78.0% 87.0% 64.0%
Factor Interactions
Volatility Expanding
60-day vol (67%) significantly exceeds 252-day (30%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
D
44.7% avg (7 factors)
Quality
C
55.4% avg (7 factors)
Momentum
B
61.1% avg (4 factors)
Risk
B
66.6% avg (1 factors)
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends6 snapshots
Factor Persistence6 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.880—6—
Value %ile0.620—0—
Quality %ile0.790—6—
Momentum %ile0.830—2—
F-Score6.000—0—
Confidence0.920—6—
Volatility0.300—0—
Value Lens2021-07-13 → 2026-07-12
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
42.11
Earnings Yield (E/P)
0.0348
Price / Sales
2.47
Price / Book
3.24
Price / Cash Flow
9.10
FCF Yield
9.0%
EBITDA / EV
5.9%
Sales Yield (1/P·S)
0.4124
Shareholder Yield
Div + net buyback / mktcap
0.4%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
7.7%
Return on Assets
4.7%
Net Margin
5.9%
Operating Margin
8.4%
Gross Profit / Assets
Novy-Marx GPA
33.9%
Current Ratio
3.25
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.170
MomentumPrice trend strength over different horizons
6M Return
57.8%
12M Return
25.8%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
11.1%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.37
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
4.4%
Earnings Growth (YoY)
-24.5%
Earnings Stability (CV)
Lower = more stable
0.504
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
6
Dividend Yield
0.4%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
41
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
37
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
59
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity